Laboratory Corporation of America Holdings (LH)
After hours:
| Previous close | 193.44 |
| Open | 193.50 |
| Bid | 192.15 x 1100 |
| Ask | 194.02 x 1000 |
| Day's range | 191.97 - 195.03 |
| 52-week range | 185.72 - 234.09 |
| Volume | |
| Avg. volume | 774,350 |
| Market cap | 16.43B |
| Beta (5Y monthly) | 1.01 |
| PE ratio (TTM) | 41.65 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.88 (1.48%) |
| Ex-dividend date | 28 May 2024 |
| 1y target est | N/A |
- PR Newswire
Labcorp to Present Multiple Abstracts across Precision Oncology at the 2024 ASCO Annual Meeting
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will present several abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago (May 31 – June 4, 2024).
- PR Newswire
Labcorp to Speak at the 44th Annual William Blair Growth Stock Conference
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that members of the executive management team will participate in a presentation at the 44th Annual William Blair Growth Stock Conference on Tuesday, June 4 at 2:00 p.m. (CT).
- PR Newswire
Labcorp Introduces First Trimester Screening Test to Assess Preeclampsia Risk during Pregnancy
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of its first trimester preeclampsia screening test to be performed between 11 and 14 weeks gestation to determine the risk of developing preeclampsia before 34 weeks of pregnancy. It is the only test of its kind available in the United States and is relevant for all pregnant individuals, including those with a low- to average-risk for preeclampsia or first-time pregnancies.
